Navigation Links
The Epilepsy Market Will Grow 2 Percent Annually Through 2022 with Expanding Uptake of Third-Generation Brands
Date:12/16/2013

BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market for epilepsy pharmacotherapies will expand at a rate of 2 percent annually through 2022, peaking at more than $4.1 billion in 2020. Market growth will be fueled primarily by increasing uptake of premium-priced third-generation antiepileptic drugs (AEDs) such as UCB's Vimpat. Capturing approximately $800 million in 2021 sales across the major pharmaceutical markets under study (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan), Vimpat will achieve the greatest clinical and commercial success in its class, capitalizing on a strong efficacy and safety profile that will drive its gradual incorporation into early lines of epilepsy treatment.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Nevertheless, the Pharmacor advisory service entitled Epilepsy finds that neurologists will continue to rely heavily on time-tested, generically available, first- and second-generation AEDs, notably levetiracetam (UCB/Otsuka's Keppra/E Keppra, generics; UCB's Keppra XR, generics) and lamotrigine (GlaxoSmithKline/Juste's Lamictal, other brands, generics; GlaxoSmithKline's Lamictal XR, generics). In contrast, the findings reveal that the uptake of newly marketed brands—Eisai's Fycompa, Sunovion Pharmaceuticals/Bial/Eisai's Zebinix/Aptiom—and emerging novel therapies—UCB's brivaracetam—will be slow as prescribers gradually adopt these newer therapies as late-line adjunctive therapy in treatment-refractory patients. Across the major markets, Decision Resources estimates that less than 15 percent of drug-treated epilepsy patients will receive a third-generation AED through 2022.  

The report also finds that in addition to the modest expected uptake of brivaracetam—the only new chemical entity forecast to launch for epilepsy through 2022—emerging reformulations of established AEDs—topiramate extended-release from Supernus (Trokendi XR), Upsher-Smith Laboratories' USL-255 and Supernus's oxcarbazepine extended-release (Oxtellar XR)—will struggle to compete with the original, immediate-release formulations, which are widely prescribed and generically available. Ultimately, interviewed experts express doubts that any of these products will meaningfully address the most pressing unmet needs in the treatment of epilepsy.

"Numerous opportunities remain for drug development in epilepsy, including improved treatments for refractory patients and disease-modifying therapeutics that prevent or reverse the mechanisms underlying recurrent seizures," said Decision Resources Business Insights Analyst John Crowley, Ph.D. "Although early-stage translational research is yielding promising new approaches to epilepsy treatment, as was showcased this month at the American Epilepsy Society Annual Meeting, the near-term clinical and commercial impact of these efforts will be minimal."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 (extended-release topiramate) In Epilepsy Patients With Refractory Partial-Onset Seizures
2. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Epilepsy and other Neurological Disorders
3. New data from UCBs epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society
4. Upsher-Smith To Present New Research On USL255 (Extended-Release Topiramate) At 2013 American Epilepsy Society Annual Meeting
5. Upsher-Smith To Present Findings From Global Phase 3 Trial Investigating USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures At 2013 American Epilepsy Society Meeting
6. GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy
7. Epilepsy Foundation Calls on Drug Enforcement Agency to Improve Review Process for New Treatments
8. Upsher-Smith Teams Up With Epilepsy Foundation Of Minnesota For 2013 Stroll For Epilepsy
9. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
10. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
11. Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... LONDON , Dec. 8, 2016  The global ... of 8.8% during the forecast period of 2016 to ... billion by 2021 from USD 18.21 billion in 2016. ... surgeries, rising incidences of sports related injuries and spinal ... and rising need of effective blood loss management. ...
(Date:12/8/2016)... KEY FINDINGS The global medical ... Various reasons for growth of the medical lifting sling ... chronic diseases, high recovery cost of injuries and government ... lifting sling refers to an assistive device that helps ... connect to the lift and hold the patient. It ...
(Date:12/8/2016)... Inc. (NYSE: DPLO) has been recognized by the Detroit Free ... To learn more about Diplomat,s career opportunities, visit ... ... ... a research firm specializing in organizational health and workplace improvement. The ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa ... (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions of ... Hoessel to vice president of sales. , Litsinger joined Mirixa in 2008 ...
(Date:12/8/2016)... ... 08, 2016 , ... With the increasing demand for dental implants, the National ... campaign to inform dentists and patients about the safety issues related to dental restorations. ... in the U.S. is projected to reach $6.4 billion in 2018 with more than ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... 10.2 version gives development continuity to its innovative Unified Instance Manager architecture, ... capacity. In addition, this new version optimizes the unattended auto-dialing system without ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...
Breaking Medicine News(10 mins):